Research progress of cellular-mesenchymal to epithelial transition factor in targeted therapy of gastric cancer
-
摘要: 胃癌是最常见的恶性肿瘤之一，严重威胁着人类的身体健康。中国胃癌的早期诊断率低，大多数患者在诊断时已处于晚期，失去了根治性手术的治疗机会，近年来，随着分子生物学的发展，分子靶向药物逐渐成为新的治疗手段，c-间充质上皮转化蛋白也称肝细胞生长因子受体，与胃癌的发生、发展、转移及预后有着密切的关系。根据公共卫生数据库(TCGA和CEO)分析，c-间充质上皮转化蛋白在胃癌组织中高表达，是胃癌极具潜力的治疗性靶点，许多针对c-间充质上皮转化蛋白的靶向药物正在临床开发中，该文对c-间充质上皮转化蛋白的研究进展进行综述。
-
关键词:
- 胃肿瘤 /
- c-间充质上皮转化蛋白 /
- 靶向治疗 /
- 研究进展
Abstract: Gastric cancer is one of the most common malignant tumors, which is a serious threat to human health.The rate of early diagnosis of gastric cancer in China is low, most of the patients at the time of diagnosis has been late, lost a radical surgical treatment opportunity, in recent years, with the development of molecular biology, molecular targeted drugs gradually become the new treatments, cellular-mesenchymal to epithelial transition factor, also known as hepatocyte growth factor receptor, is closely related to the occurrence, development, metastasis and prognosis of gastric cancer. According to the analysis of public health database (TCGA and CEO), cellular-mesenchymal to epithelial transition factor is highly expressed in gastric cancer tissues and is a promising therapeutic target for gastric cancer.Many targeted drugs for cellular-mesenchymal to epithelial transition factor are under clinical development.This article reviews the research progress of cellular-mesenchymal to epithelial transition factor. -
-
[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2] 杨之洵, 郑荣寿, 张思维, 等. 中国胃癌发病趋势及预测[J]. 中国肿瘤, 2019, 28(5): 321-326. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201905001.htm
[3] Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives[J]. World J Gastroenterol, 2014, 20(14): 3905-3915. doi: 10.3748/wjg.v20.i14.3905
[4] Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2): 167-192. doi: 10.6004/jnccn.2022.0008
[5] Kahraman S, Yalcin S. Recent advances in systemic treatments for HER-2 positive advanced gastric cancer[J]. Onco Targets Ther, 2021, 14: 4149-4162. doi: 10.2147/OTT.S315252
[6] Pereira MA, Ramos MFKP, Dias AR, et al. Expression profile of markers for targeted therapy in gastric cancer patients: HER-2, microsatellite instability and PD-L1[J]. Mol Diagn Ther, 2019, 23(6): 761-771. doi: 10.1007/s40291-019-00424-y
[7] 年瑞, 李万军, 李维华. 胃腺癌组织c-MET EGFR和HER-2的表达与病理特征及预后关系研究[J]. 肿瘤代谢与营养电子杂志, 2022, 9(1): 61-65. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLDX202201009.htm
[8] 候涛涛. HGF/c-met在胃癌中的表达及对胃癌细胞生长和迁移的影响[D]. 沈阳: 中国医科大学, 2020.
[9] El Darsa H, El Sayed R, Abdel-Rahman O. MET inhibitors for the treatment of gastric Cancer: what's their potential?[J]. J Exp Pharmacol, 2020, 12: 349-361. doi: 10.2147/JEP.S242958
[10] Cooper CS, Blair DG, Oskarsson MK, et al. Characterization of human transforming genes from chemically transformed, teratocarcinoma, and pancreatic carcinoma cell lines[J]. Cancer Res, 1984, 44(1): 1-10.
[11] Wang C, Xi W, Ji J, et al. The prognostic value of HGF-c-MET signaling pathway in Gastric Cancer: a study based on TCGA and GEO databases[J]. Int J Med Sci, 2020, 17(13): 1946-1955. doi: 10.7150/ijms.44952
[12] 朱雪茹, 郑磊贞. HGF/c-Met与胃癌靶向治疗的研究进展[J] 上海交通大学学报(医学版), 2016, 36(1): 133-137. doi: 10.3969/j.issn.1674-8115.2016.01.027
[13] 徐倩文, 孟迪, 孙秀威. HGF/c-Met在肝细胞癌中作用的研究进展[J]. 现代肿瘤医学, 2022, 30(8): 1504-1507. doi: 10.3969/j.issn.1672-4992.2022.08.034
[14] Parizadeh SM, Jafarzadeh-Esfehani R, Fazilat-Panah D, et al. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer[J]. IUBMB Life, 2019, 71(7): 802-811.
[15] Matsumoto K, Umitsu M, De Silva DM, et al. Hepatocyte growth factor/MET in cancer progression and biomarker discovery[J]. Cancer Sci, 2017, 108(3): 296-307. doi: 10.1111/cas.13156
[16] Noguchi E, Saito N, Kobayashi M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression[J]. Mol Med Rep, 2015, 11(5): 3423-3431.
[17] Shao Z, Pan H, Tu S, et al. HGF/c-Met Axis: The advanced development in digestive system cancer[J]. Front Cell Dev Biol, 2020, 8: 801. doi: 10.3389/fcell.2020.00801
[18] Koch JP, Aebersold DM, Zimmer Y, et al. MET targeting: time for a rematch[J]. Oncogene, 2020, 39(14): 2845-2862. doi: 10.1038/s41388-020-1193-8
[19] Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities[J]. Mol Cancer, 2018, 17(1): 1-14. doi: 10.1186/s12943-017-0753-1
[20] Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy[J]. Nat Rev Cancer, 2018, 18(6): 341-358.
[21] Wang X, He L, Wang Y, et al. MiR-300 Alleviates Cell Proliferation and Migration and Facilitates Cell Apoptosis by Targeting c-Met in Gastric Cancer[J]. J Oncol, 2022, 2022: 6167554.
[22] Puccini A, Marin-Ramos NI, Bergamo F, et al. Safety and tolerability of c-MET inhibitors in cancer[J]. Drug Saf, 2019, 42(2): 211-233. doi: 10.1007/s40264-018-0780-x
[23] Higashijima Y, Kanki Y. Molecular mechanistic insights: The emerging role of SOXF transcription factors in tumorigenesis and development[J]. Semin Cancer Biol, 2020, 67(Pt1): 39-48.
[24] Yang Y, Wang C, Dai C, et al. Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1[J]. Acta Biochim Biophys Sin, 2021, 53(5): 547-557. doi: 10.1093/abbs/gmab026
[25] Kim ST, Lee S, Park M, et al. Combination of docetaxel plus savolitinib in refractory cancer patients: a report on phaseⅠTrial[J]. Transl Oncol, 2019, 12(4): 597-601. doi: 10.1016/j.tranon.2018.12.009
[26] Lee J, Kim ST, Kim K, et al. Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial[J]. Cancer Discov, 2019, 9(10): 1388-1405.
[27] Markham A. Savolitinib: First Approval[J]. Drugs, 2021, 81(14): 1665-1670.
[28] Wang Y, Liu T, Chen G, et al. Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers[J]. Oncologist, 2022, 27(5): 342-e383.
[29] Tacar SY, Yilmaz M, Oz B, et al. Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience[J]. Tumori, 2022, 108(3): 258-262.
[30] Ji J, Chen W, Lian W, et al. (S)-crizotinib reduces gastric cancer growth through oxidative DNA damage and triggers pro-survival akt signal[J]. Cell Death Dis, 2018, 9(6): 1-15.
[31] Liu M. Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report[J]. Medicine, 2021, 100(36): e27017.
[32] Gortany NK, Panahi G, Ghafari H, et al. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition[J]. Cancer Chemother Pharmacol, 2021, 87(6): 827-842.
[33] Grojean M, Schwarz MA, Schwarz JR, et al. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models[J]. J Cell Mol Med, 2021, 25(11): 4950-4961.
[34] Sohn SH, Kim B, Sul HJ, et al. Foretinib inhibits cancer stemness and gastric cancer cell proliferation by decreasing CD44 and c-MET signaling[J]. Onco Targets Ther, 2020, 13: 1027-1035.
[35] Koustas E, Karamouzis MV, Sarantis P, et al. Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models[J]. J Cell Mol Med, 2020, 24(18): 10420-10431.
[36] Sohn SH, Kim B, Sul HJ, et al. INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification[J]. BMC Res Notes, 2019, 12(1): 1-7.
[37] Esaki T, Hirai F, Makiyama A, et al. Phase I dose-escalation study of capmatinib(INC280) in Japanese patients with advanced solid tumors[J]. Cancer Sci, 2019, 110(4): 1340-1351.
[38] Jiang Z, Cai Z, Ma Q, et al. Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis[J]. BMJ Open, 2021, 11(12): e049575.
[39] DoiT, Yamaguchi K, Komatsu Y, et al. A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer[J]. Jpn J Clin Oncol, 2017, 47(11): 1002-1009.
[40] Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer(RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1467-1482.
[41] Malka D, François E, Penault-Llorca F, et al. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma(PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase Ⅱ trial[J]. Eur J Cancer, 2019, 115: 97-106.
[42] Palle J, Hirsch L, Lapeyre-Prost A, et al. Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients[J]. Cancers, 2021, 13(21): 5562.
[43] Luo G, Guo B, Wu L, et al. Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study[J]. Evid Based Complement Alternat Med, 2022, 2022: 1976788.
[44] Kim BJ, Kim YJ, Sohn SH, et al. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification[J]. Invest New Drugs, 2020, 38(6): 1633-1640.
-
计量
- 文章访问数: 919
- PDF下载数: 328
- 施引文献: 0
下载: